Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of Single Dose RO5313534 in Healthy Volunteers, and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: September 3, 2010
Last updated: November 1, 2016
Last verified: November 2016
This open-label, fixed sequence, two-period study will assess the effect of memantine on the pharmacokinetics, safety and tolerability of a single oral dose of RO5313534 and the effect of RO5313534 on safety and tolerability of steady-state memantine. Healthy volunteers will receive a single oral dose of RO5313534 on Day 1 of Treatment Period 1 (3 days). After a washout period of 5-21 days, oral memantine will be administered on Days 1-21 of Treatment Period 2 and a single dose of RO5313534 on Day 19. There will be a follow-up of 3-4 weeks after the last dose. Anticipated time on study for each volunteer is up to 14 weeks.

Condition Intervention Phase
Healthy Volunteer
Drug: RO5313534
Drug: memantine
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Single Center, Open-label, Fixed Sequence, Two-period Study to Investigate the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of RO5313534 After Single Dose Administration in Healthy Volunteers and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Effect of multiple-dose memantine on single-dose pharmacokinetics of RO5313534 and of RO5313534 on steady-state pharmacokinetics of memantine [ Time Frame: Days 16-21 ]

Secondary Outcome Measures:
  • Effect of multiple-dose memantine on safety and tolerability of single-dose RO5313534 [ Time Frame: up to 14 weeks ]
  • Safety and tolerability of memantine alone and in combination with a single dose of RO5313534 [ Time Frame: up to 7 weeks ]

Enrollment: 16
Study Start Date: September 2010
Estimated Study Completion Date: November 2010
Arms Assigned Interventions
Experimental: Single Arm Drug: RO5313534
single oral dose
Drug: memantine
multiple doses to steady state


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males and females, 18 to 45 years of age inclusive
  • Body mass index (BMI) 18-30 kg/m2
  • Male subjects must agree to use a barrier method of contraception from first dosing until the end of the study
  • Female subjects must be either surgically sterile or agree to use two forms of contraception until the end of the study
  • Non-smoker for at least 6 months

Exclusion Criteria:

  • Clinically significant history or detection during medical interview/physical examiation of any disease or condition that is capable of altering the absorption. metabolism or elimination of drugs, or would constitute a risk factor when taking the study drug
  • History of drug addiction or alcohol abuse
  • Any confirmed significant allergic reaction to any drug, or multiple allergies in the judgement of the investigator
  • Positive serology to hepatitis B or hepatitis C or Human Immunodeficiency Viruses (HIV type 1 and 2) at screening
  • Pregnant or lactating women
  • Participation in an investigational drug or device study within the last 3 months prior to first dose
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01196065

Rennes, France, 35042
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01196065     History of Changes
Other Study ID Numbers: BP25180
Study First Received: September 3, 2010
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents processed this record on May 25, 2017